|
CN112062717A
|
|
Indoleamine 2, 3-dioxygenase inhibitor
|
|
WO2020228806A1
|
|
Antibody against claudin 18a2 and use thereof
|
|
CN112225749A
|
|
Crystal form of doriravir sodium and preparation method thereof
|
|
CN112142678A
|
|
Rilpivirine dimer, intermediate thereof, preparation method and application thereof
|
|
CN111892590A
|
|
New piparib new intermediate, crystal form and preparation method thereof
|
|
CN111777576A
|
|
Preparation method of nintedanib key intermediate
|
|
CN111704574A
|
|
Preparation method of high-purity sorafenib tosylate crystal form III
|
|
CN111689897A
|
|
Preparation method of high-purity Levatinib mesylate crystal form C
|
|
CN111388419A
|
|
Aprepitant emulsion
|
|
CN111217879A
|
|
Preparation method of high-purity obeticholic acid intermediate crystal form
|
|
CN111196807A
|
|
Recovery preparation method of avibactam sodium
|
|
CN111171005A
|
|
Tipirimidyl hydrochloride impurity compound and preparation method and application thereof
|
|
CN111110627A
|
|
Amikacin sulfate injection and preparation method thereof
|
|
CN110894198A
|
|
Xanthine compound and preparation method and application thereof
|
|
CN110893176A
|
|
Preparation method of rivaroxaban-containing pharmaceutical composition
|
|
CN110865129A
|
|
Method for detecting multiple modification levels in dolabric
|
|
CN110824096A
|
|
Method for analyzing protein mismatching disulfide bond
|
|
CN110776429A
|
|
Improved preparation method of rasagiline racemic intermediate
|
|
CN110404066A
|
|
A kind of monoclonal antibody formulation of anti-human PD-1, combination medicine and application thereof
|
|
CN110407877A
|
|
The polymorphic of novel loop coil aryl phosphorous oxides
|
